Want to see FR:CVX full AI Analyst Report?
Top Page
Affluent Medical SA
(CVX)
Select Model
Select Model
Rating:52Neutral
Price Target:
€7.00
▲(25.90% Upside)
Action:Reiterated
Date:07/31/26
The score is held down primarily by weak financial performance (zero 2025 revenue, widening losses, rising leverage, and sustained cash burn), which increases financing risk. Technicals provide a partial offset as the stock trades above key moving averages, but valuation remains constrained by negative earnings and no stated dividend yield.
Positive Factors
Diverse clinical-stage pipeline
Affluent’s portfolio spans structural heart, vascular and urology devices, spreading scientific and commercial risk across multiple programs. Multiple development-stage candidates create several independent regulatory and partnerable milestones, improving long-term optionality for commercialization.
Negative Factors
Zero 2025 revenue and widening losses
Reporting zero annual revenue in 2025 and materially wider losses demonstrates the company remains pre-revenue and far from operating leverage. Persistent negative gross profit undermines the path to self-sustaining margins and increases the likelihood of prolonged external funding needs.
Read all positive and negative factors
Positive Factors
Negative Factors
Diverse clinical-stage pipeline
Affluent’s portfolio spans structural heart, vascular and urology devices, spreading scientific and commercial risk across multiple programs. Multiple development-stage candidates create several independent regulatory and partnerable milestones, improving long-term optionality for commercialization.
Read all positive factors
Affluent Medical SA (CVX) vs. iShares MSCI France ETF (EWQ)
Market Cap
€385.96M
Dividend YieldN/A
Average Volume (3M)9.49K
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue Growth-100.00%
EPS Growth-50.15%
CountryFR
Employees104
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.64
Shares Outstanding62,275,177
10 Day Avg. Volume9,769
30 Day Avg. Volume9,492
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)12.26
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.45
Revenue Forecast (FY)€1.71M
Affluent Medical SA Business Overview & Revenue Model
Company Description
Carvolix S.A. operates as a medical technology firm, concurrently involved in both commercialization and clinical development, specializing in treatment solutions for structural heart ailments and cerebral strokes. The company's innovative endeavo...
How the Company Makes Money
As a development-stage medtech company, Affluent Medical’s business model is primarily based on advancing its device candidates through R&D, preclinical and clinical studies, and regulatory pathways with the aim of future commercialization. Public...
Affluent Medical SA Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 4.12M | 1.22M | 1.34M | 1.45M |
| Gross Profit | -2.19M | -9.27M | -1.20M | -1.10M | -1.29M |
| EBITDA | -15.81M | -13.44M | -13.34M | -13.21M | -10.89M |
| Net Income | -24.97M | -14.74M | -15.65M | -15.23M | -14.82M |
Balance Sheet | |||||
| Total Assets | 47.83M | 60.86M | 56.62M | 60.02M | 70.03M |
| Cash, Cash Equivalents and Short-Term Investments | 1.76M | 6.62M | 1.66M | 2.58M | 11.41M |
| Total Debt | 24.04M | 16.33M | 17.13M | 17.73M | 19.75M |
| Total Liabilities | 42.28M | 30.59M | 25.15M | 26.19M | 26.50M |
| Stockholders Equity | 5.55M | 30.27M | 31.47M | 33.83M | 43.53M |
Cash Flow | |||||
| Free Cash Flow | -11.72M | -11.47M | -12.24M | -11.23M | -12.70M |
| Operating Cash Flow | -11.61M | -11.32M | -12.05M | -11.08M | -12.36M |
| Investing Cash Flow | 5.25M | -480.00K | -184.00K | -146.00K | -160.00K |
| Financing Cash Flow | 6.88M | 11.37M | 11.32M | 2.40M | 18.28M |
Affluent Medical SA Technical Analysis
Positive
5.56
Price Trends
4.76
Positive
3.94
Positive
3.08
Positive
Market Momentum
0.37
Positive
56.30
Neutral
44.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:CVX, the sentiment is Positive. The current price of 5.56 is below the 20-day moving average (MA) of 6.06, above the 50-day MA of 4.76, and above the 200-day MA of 3.08, indicating a bullish trend. The MACD of 0.37 indicates Positive momentum. The RSI at 56.30 is Neutral, neither overbought nor oversold. The STOCH value of 44.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:CVX.
Affluent Medical SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | €385.96M | -9.50 | -187.32% | ― | -100.00% | -50.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €204.13M | -3.60 | 90.10% | ― | 1.79% | 15.89% | |
47 Neutral | €44.30M | -5.45 | 222.05% | ― | 42.86% | 13.93% | |
46 Neutral | €29.56M | 7.67 | -58.93% | ― | 7.43% | ― | |
42 Neutral | €25.71M | -5.84 | 912.92% | ― | 32.62% | 7.10% |
* Healthcare Sector Average
FR:CVX
Affluent Medical SA
6.08
4.70
340.58%
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.16
0.05
51.96%
FR:ALTHE
Theraclion SA
0.59
<0.01
0.34%
FR:ALDMS
Diagnostic Medical Systems
1.09
-0.23
-17.74%
FR:ALMDT
Median Technologies
4.14
2.05
98.32%
FR:ALIMP
Implanet SA
0.18
0.01
7.88%
Affluent Medical SA Corporate Events
ODDO BHF Launches Outperformance Coverage on Carvolix, Signaling Strong Upside Potential
Jul 29, 2026
Carvolix has gained fresh attention in the equity markets after ODDO BHF initiated coverage of the stock with an Outperformance recommendation and a price target of €10.5, implying an 89% upside from the prior closing price. The new rating b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.